Addiction and Liver Disease: Exploring the Complex Relationship and Implications for Clinical Management

期刊论文
发表日期：

2024年1月23日

查看全文

David Hudson,
Nisha Howarth,
Francisco Idalsoaga,
Yi Nong Song,
Alvi Islam,
Saranya Theiventhiran,
Luis Antonio Díaz,
Juan Pablo Arab

摘要

Purpose of Review

The review focuses on addressing substance use disorders in individuals with chronic liver disease, specifically alcohol, tobacco, and cannabis.

Recent Findings

Psychological interventions and medications like naltrexone and acamprosate are effective in treating alcohol use disorder in patients with liver disease. Tobacco smoking has a negative impact on fibrosis progression, it is recommended to regularly screen and provide structured brief interventions in combination with medications like varenicline and nicotine replacement therapy. Cannabis use disorder is associated with adverse health outcomes, and psychological therapy is preferred; pharmaceutical agents are not currently recommended.

Summary

A combination of psychological interventions and medication is recommended for treating substance use disorders in patients with advanced liver disease.